Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) scored a legal victory when a district court ruled that its patent rights of its Eylea retinal-disease drug were infringed upon by rival Viatris Inc. (NASDAQ:VTRS).
According to a Bloomberg report, Regeneron sued Viatris’ Mylan unit in August 2022, claiming that its proposed biosimilar copy of Eylea infringed 24 of its patents. The lawsuit was later adjusted to allege Viatris ran afoul of only three patents.
The U.S. District Court for the Northern District of West Virginia ruled in Regeneron’s favor by stating the Tarrytown-based company “has demonstrated by a preponderance of the evidence that the Defendants have infringed claims 4, 7, 9, 11, 14, 15, 16, and 17 of the ’865 Patent; Regeneron has demonstrated by a preponderance of the evidence that the Defendants will induce infringement of claims 6 and 25 of the ’572 Patent and claims 11 and 19 of the ’601 Patent.”
